Comparative analysis of European guideline-based clinicopathological risk groups and the International Federation of Gynecology and Obstetrics staging system for endometrial cancer

被引:0
|
作者
Loukovaara, Mikko J. [1 ,2 ,3 ]
Pasanen, Annukka M. [4 ,5 ]
Lassus, Heini J. [1 ,2 ]
Luomaranta, Anna L. [1 ,2 ]
Hellberg, Piret [1 ,2 ]
Vartiainen, Johanna [1 ,2 ]
Tapper, Johanna E. [1 ,2 ]
Butzow, Ralf C. [1 ,2 ,4 ,5 ]
机构
[1] Helsinki Univ Hosp, Dept Obstet & Gynecol, POB 180 HUS, Helsinki 00029, Finland
[2] Univ Helsinki, POB 180 HUS, Helsinki 00029, Finland
[3] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland
[4] Helsinki Univ Hosp, Dept Pathol, Helsinki, Finland
[5] Univ Helsinki, Fac Med, Res Program Appl Tumor Genom, Helsinki, Finland
关键词
Endometrial cancer; Mismatch repair; Polymerase-is an element of; p53; Stage; Survival; CELL-ADHESION MOLECULE; CLASSIFICATION; CARCINOMA;
D O I
10.1016/j.ejogrb.2025.02.049
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To investigate the correlation between endometrial cancer risk groups, as defined by the 2021 European guidelines, and the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system. Further, we aimed to evaluate the additional prognostic capability of the staging system within individual risk groups. Study design: This retrospective cohort study included patients who underwent primary treatment for endometrial cancer at a single tertiary center. Each case was classified into a molecular-integrated risk group according to the 2021 joint guidelines from the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP). Staging was performed using the FIGO 2023 criteria with molecular classification. Results: Data from 1044 patients were analyzed. Median follow-up was 70 months. Stage IA2, stage IB, and stage IVB were the most prevalent stages among the ESGO-ESTRO-ESP low-risk, intermediate risk, and advanced- metastatic groups, accounting for 80 %, 75 %, and 54 % of the cases, respectively. The stage distribution was more heterogeneous in the high-intermediate risk and high-risk groups, with stage IIA comprising 36 % and stage IICmp53abn comprising 35 % of cases in these groups. The FIGO staging system further stratified survival outcomes especially in the high-intermediate and high-risk groups. Stage IIC included a substantial number of cases from the intermediate risk (n = 23), high-intermediate risk (n = 48), and high-risk (n = 27) groups. Risk groups were associated with survival within this stage. Conclusions: ESGO-ESTRO-ESP high-intermediate risk and high-risk endometrial cancers exhibited the greatest variability in terms of stage distribution and survival outcomes. Stage IIC, the most heterogeneous stage concerning risk groups, showed an association between risk groups and survival.
引用
收藏
页码:85 / 89
页数:5
相关论文
共 50 条
  • [31] Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study.
    FadiAbuShahin
    JimOrr
    中国肿瘤临床, 2010, 37 (02) : 124 - 124
  • [32] Possible Risk Factors of Pulmonary Metastases in Patients With International Federation of Gynecology and Obstetrics Stage I Endometrioid-Type Endometrial Cancer
    Jiang, Wei
    Chen, Jun
    Tao, Xiang
    Huang, Feifei
    Zhu, Menghan
    Wang, Chao
    Feng, Weiwei
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (06) : 1195 - 1204
  • [33] 2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both
    Rios-Doria, Eric
    Abu-Rustum, Nadeem R.
    Glaser, Gretchen
    Mcgree, Michaela
    Eriksson, Ane Gerda
    Pham, Melissa
    Soliman, Pamela
    Ataseven, Beyhan
    Alektiar, Kaled
    Zamarin, Dmitriy
    Leitao, Mario L., Jr.
    Mueller, Jennifer
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
  • [34] Lymphadenectomy and chemotherapy are effective treatments for patients with 2023 international federation of gynecology and obstetrics stage IIC-high risk endometrial cancer in Japan
    Tani, Yoshinori
    Nakamura, Keiichiro
    Yorimitsu, Masae
    Seki, Noriko
    Nakanishi, Mie
    Itou, Hironori
    Shimizu, Miyuki
    Yamamoto, Dan
    Takahara, Etsuko
    Masuyama, Hisashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (01) : 144 - 156
  • [35] Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management
    Hwang, Lindsay
    Bailey, April
    Lea, Jayanthi
    Albuquerque, Kevin
    FUTURE ONCOLOGY, 2015, 11 (02) : 309 - 322
  • [37] NATIONAL SURVEY OF OVARIAN CARCINOMA-VI - CRITICAL-ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING SYSTEM
    NGUYEN, HN
    AVERETTE, HE
    HOSKINS, W
    SEVIN, BU
    PENALVER, M
    STEREN, A
    CANCER, 1993, 72 (10) : 3007 - 3011
  • [39] Is the International Federation of Gynecology and Obstetrics staging system for cervical carcinoma able to predict survival in patients with cervical carcinoma? An assessment of clinimetric properties
    Kupets, R
    Covens, A
    CANCER, 2001, 92 (04) : 796 - 804
  • [40] Clinical Outcomes in International Federation of Gynecology and Obstetrics Stage IA Endometrial Cancer With Myometrial Invasion Treated With or Without Postoperative Vaginal Brachytherapy
    Diavolitsis, V.
    Rademaker, A.
    Lurain, J.
    Hoekstra, A.
    Strauss, J.
    Small, W., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (02): : 415 - 419